Markus Kostrzewa (Bruker Daltonik GmbH)

Kostrzewa, Markus (Bruker 200910 Bruker Daltonik GmbH Director Molecular Biology R&D)

	Organisation	Bruker Daltonik GmbH
	Group	Bruker Corporation (Group)
	Product	mass spectrometer
	Product 2	diagnostics (medical/biological)

Bruker Daltonics, Inc.. (3/18/02). "Press Release: Bruker Daltonics Launches GenoLink™ – an Automated SNP Genotyping Accessory to Accelerate Functional Genomics Reserach". New Orleans, Louisiana.

Bruker Daltonics Inc. (NASDAQ: BDAL) today introduces GenoLink™, an automated accessory for MALDI-TOF mass spectrometry-based SNP genotyping at the 2002 Pittsburgh Conference. GenoLink complements the Bruker Daltonics Proteineer™ suite and its MALDI-TOF systems for proteomics, by adding an automated accessory for SNP genotyping. By interfacing GenoLink with the Proteineer suite, Bruker Daltonics targets functional genomics studies, where researchers wish to analyze both genetic variations and protein expression.

GenoLink combines semi-automated sample preparation, automated MALDI-TOF analysis and bioinformatics to achieve very high accuracy with direct label-free SNP genotyping. GenoLink incorporates our new mapII/pure™ robot to perform semi-automated sample processing, genopure™ magnetic bead DNA purification and AnchorChip™ MALDI target preparation. GenoLink is an accessory that can be integrated with Bruker Daltonics' autoflex™ or ultraflex™ MALDI-TOF mass spectrometers to detect SNPs within a few seconds per sample. The SNPs are automatically assigned by our genotools™ bioinformatics software, which also performs quality control.

GenoLink addresses the needs of MALDI-TOF customers primarily focused on proteomics research. Our strategic partners, Sequenom and Variagenics, offer dedicated high-throughput SNP genotyping solutions based on MALDI-TOF worldwide.

Dr. Hanno Langen, Head of Proteomics, at Roche (Basel, Switzerland) commented on the new GenoLink solution: "Linking genomics and proteomics is essential for an in-depth understanding of cellular functions. The linked MALDI platform is ideally suited for bridging genomics and proteomics with the same technology." Dr. Dorothee Foernzler, Head of Human Genetics Laboratories at Roche, added: "Combining genetics, gene expression and proteomics approaches like this opens very powerful and indispensable new ways for drug discovery and development."

About Bruker Daltonics

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com.

Safe-Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements of Bruker Daltonics as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.

Contact:
Markus Kostrzewa, Ph.D.
Head of Bioanalytical Development
Telephone +49-341-2431-354
Email: km@bsax.de

Record changed: 2012-04-02

Follow Us!

Top News

Upcoming Events

Associations

Partners

Markus Kostrzewa (Bruker Daltonik GmbH)

Bruker Daltonics, Inc.. (3/18/02). "Press Release: Bruker Daltonics Launches GenoLink™ – an Automated SNP Genotyping Accessory to Accelerate Functional Genomics Reserach". New Orleans, Louisiana.

More documents for Markus Kostrzewa